Detalhe da pesquisa
1.
A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
Cancer
; 121(4): 570-9, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25312684
2.
A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.
Invest New Drugs
; 32(1): 171-7, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24173965
3.
Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures.
FASEB J
; 24(8): 2928-37, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20335225
4.
A Patient Experience Course Syllabus: Integrating Service Sciences Research to Enhance Health-Care Delivery.
J Patient Exp
; 7(4): 449-453, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33062860
5.
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33046621
6.
Acoustic activation of targeted liquid perfluorocarbon nanoparticles does not compromise endothelial integrity.
IEEE Trans Nanobioscience
; 5(2): 69-75, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16805101
7.
Postformulation peptide drug loading of nanostructures.
Methods Enzymol
; 508: 17-39, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22449919
8.
Cytolytic peptide nanoparticles ('NanoBees') for cancer therapy.
Wiley Interdiscip Rev Nanomed Nanobiotechnol
; 3(3): 318-27, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21225660
9.
Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth.
J Clin Invest
; 119(9): 2830-42, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19726870
10.
Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides.
Nano Lett
; 8(4): 1131-6, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18302330